Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

Figure 1

REMARK diagram detailing FFPE tissue and sample availability in the present study for the application of different analytical techniques for the determination of HER2 and TOP2A gene status, mRNA and protein expression. The rates in parentheses for CISH, qRT-PCR and IHC were calculated against the number of tissue samples with at least one HER2 or TOP2A value available (n = 352).

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us